Press releases
Galenica reports strong sales growth once again
Ad hoc announcement pursuant to Art. 53 LR, Thursday, 23 January 2025
Galenica Group sales once again performed very positively in 2024, with growth of 4.7% to CHF 3,922 million. As a result, Galenica outperformed the entire pharmaceutical market in terms of growth (+3.5%, IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).
Galenica increases sales growth in the third quarter
Ad hoc announcement pursuant to Art. 53 LR, Thursday, 24 October 2024
Following solid sales growth of 2.6% in the first half of 2024, Galenica grew more strongly again in the third quarter and generated net sales of CHF 2,864.8 million to the end of September 2024. With growth of 4.1%, Galenica outperformed the growth of the overall pharmaceutical market (+2.9%, IQVIA, pharmaceutical market Switzerland, YTD September 2024).
Galenica achieves solid growth in a challenging market environment
Ad hoc announcement pursuant to Art. 53 LR, Tuesday, 6 August 2024
Galenica Group sales grew by 2.6% to CHF 1,900.0 million in the first half of 2024. Both the “Products & Care” segment and the “Logistics & IT” segment contributed to the sales growth, with growth of 3.1% and 3.0% respectively. As a result, Galenica Group sales developed more dynamically than the market.